

[x](#)

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POLYSORBAT SPECIFIC	USP35–NF30	1919	28-Sep-2012	1-Oct-2012	USP37–NF32	First	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E 20	TESTS/ <i>Acid Value</i>							<i>Supplement to USP36–NF31</i>	<i>Sample: Change 10.0 to: 10.0 g</i>
POLYSORBATE 60	SPECIFIC TESTS/ <i>Acid Value</i>	<i>USP35–NF30</i>	1920	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<i>Line 1 of Sample: Change 10.0 to: 10.0 g</i>
SODIUM HYDROXIDE	ASSAY/ <i>Procedure</i>	<i>USP35–NF30</i>	1955	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<i>Line 10 of Analysis: Change Result = $\{[(V_{S1} ? V_B) \times N \times F_1]/W\} \times 100$ to: Result = $\{[(V_{S2} ? V_B) \times N \times F_1]/W\} \times 100$ AND Line 11 of Analysis: Change V_{S1} to: V_{S2}</i>
TREHALOSE	ADDITIONAL REQUIREMENTS/ <i>USP</i>	<i>USP35–NF30</i>	2007	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<i>Line 2: Delete USP Glycerin RS</i>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZEIN	Reference Standards <11> IDENTIFICATION/ C. SDS- Polyacrylamide Gel Electrophoresis	USP35–NF30	2019	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Lines 1 and 2 of the Acceptance criteria: Change Zein has two major bands: the ? band is at 21–25 kDa, and the ? band is at 17–18 kDa. to: Zein has two major bands for ?-zein at 19–26 kDa.
ACETAZOLAMIDE FOR INJECTION	ASSAY	USP35–NF30	2063	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Line 19: Change 25C(A _U /A _S) to: 250C(A _U /A _S)
ADENOSINE	IDENTIFICATION/ Infrared Absorption <197M>	USP35–NF30	2079	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Line 1: Delete NMT 0.1%
ALPRAZOLAM ORALLY-DISINTEGRATING TABLETS	IMPURITIES/ Procedure	USP35–NF30	2106	28-Sep-2012	1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Change the subsection Buffer and Diluent: Prepare as directed in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
									the Assay. to: <i>Diluent</i>: Prepare as directed in the Assay. <i>Buffer</i>: 6.8 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 3.0.
AMOXICILLIN TABLETS	PERFORMANCE TESTS	USP35–NF30	2202	28-Sep-2012		1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	Line 4 of <i>Analysis</i>: Change $\text{Result} = (r_U/r_S) \times (C_S/L) \times (D/V) \times P \times F \times 100$ to: $\text{Result} = (r_U/r_S) \times (C_S/L) \times V \times D \times P \times F \times 100$ AND Transpose lines 12 and 13 of the variable definition list to match the order in the equation Line 1: Change
CHLOROPHYL SPECIFIC		USP35–NF30	2628	28-Sep-2012		1-Oct-2012	USP37–NF32	First	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LIN COPPER COMPLEX SODIUM FLUTICASONE IM PROPIONATE	TESTS/ <i>Loss on Drying</i> <231> PURITIES/ <i>Organic Impurities</i>	USP35–NF30	3261	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>Supplement to USP36–NF31</i> <i>First Supplement to USP36–NF31</i>	150° to: 105° Line 1 of the <i>Sample solution</i> : Change 2.0 mg/mL to: 0.2 mg/mL Line 1 of <i>Internal standard solution</i> : Change 4 mg per mL to: 0.4 mg per mL Line 6 of <i>Chromatographic system</i> in the subsection <i>Column</i> : Change G14 to: G16 Lines 6 and 7 of <i>Procedure</i> : Change
GANCICLOVIR ORAL SUSPENSION	ASSAY	USP35–NF30	3319	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	
INDINAVIR SULFATE	OTHER COMPONENTS/ <i>Procedure 2: Content of Alcohol</i>	USP35–NF30	3489	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	
METFORMIN HYDROCHLORIDE TABLETS	<i>Dissolution</i> <711>/ <i>Test 3</i>	USP35–NF30	3830	28-Sep-2012		1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METRONIDAZ OLE	Related compounds	USP35–NF30	3905	28-Sep-2012		1-Oct-2012	USP37–NF32	First Supplement to USP36–NF31	$\frac{U \times C_S \times 900 \times 100}{r_S \times D \times LC}$ to: $\frac{r_U \times C_S \times 1000 \times 100}{r_S \times D \times LC}$ AND Line 11 of <i>Procedure</i> : Change 900 is the volume to: 1000 is the volume Line 19 of <i>Procedure</i> : Change r_i is the peak response for any unspecified degradation product peak in the <i>Test solution</i> to: r_i is the peak response for any single unspecified impurity in the

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NAFTIFINE HY DROCHLORID E GEL	<i>Content of alcohol</i>	USP35–NF30 3983	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	<i>Test solution</i> Line 4 of <i>Procedure:</i> Change Calculate the quantity, in mg, of C ₂ H ₅ OH in the portion of Gel taken by the formula: to: Calculate the percentage of C ₂ H ₅ OH in the portion of Gel taken by the formula:
POLYVINYL ALCOHOL	<i>Identification test C</i>	USP35–NF30 4351	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 5: Change Add 10 mL of alcohol to the remaining 5 mL of the polyvinyl alcohol solution, and mix to: Add 10 mL of alcohol to the remaining 2 mL of the polyvinyl alcohol solution, and mix.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POVIDONE	IM PURITIES/ <i>Limit of Aldehydes</i>	USP35–NF30	4379	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 15 of <i>Analysis</i>: Change $\text{Result} = 10 \times (C/W) \times \{[(A_{U2} ? A_{U1}) \times (A_{B2} ? A_{B1})]/[(A_{S2} ? A_{S1}) ? (A_{B2} ? A_{B1})] \}$ to: $\text{Result} = 100 \times (C_S/C_U) \times \{[(A_{U2} ? A_{U1}) ? (A_{B2} ? A_{B1})]/[(A_{S2} ? A_{S1}) ? (A_{B2} ? A_{B1})] \}$ AND Line 17 of <i>Analysis</i>: Change $C =$ concentration of acetaldehyde in the <i>Standard solution</i> (mg/mL) $W =$ weight of Povidone taken (g) to: $C_S =$ concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POVIDONE	IM PUR ITIES/ <i>Vinylpyrrolidone</i>	<i>USP35–NF30</i>	4379	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	acetaldehyde in the <i>Standard solution</i> (mg/mL) C_U = concentration of <i>Sample solution</i> (mg/mL) Line 2 of the Note in <i>Column, Analytical in Chromatographic system</i> : Change 4.0- × 30-mm or a 4.6- × 30-mm guard column to: 4.0-mm × 30-mm or a 4.6-mm × 30-mm guard column
PRILOCAINE AND EPINEPHRINE INJECTION	<i>Assay for epinephrine</i>	<i>USP35–NF30</i>	4411	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 7 of <i>Procedure</i> : Change 183.21/333.30 to: 183.20/333.29 AND Line 8 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<i>Procedure:</i> Change 183.21 and 333.30 to: 183.20 and 333.29
RIBAVIRIN TABLETS	ASSAY/ <i>Procedure</i>	USP35–NF30	4544	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 5 of <i>System suitability</i> in subsection <i>Tailing factor:</i> Change NLT 2.0 to: NMT 2.0
TYROSINE	IM PUR ITIES/ <i>Heavy Metals</i> <231>	USP35–NF30	4976	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 1: Change <i>Method I</i> to: <i>Method II</i>
VINORELBINE TARTRATE	ASSAY/ <i>Procedure</i>	USP35–NF30	5027	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>	Line 1 of <i>Relative standard deviation</i> in <i>System suitability:</i> Change NLT 2.0% to: NMT 2.0%
ZINC	IM	USP35–NF30	5068	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First</i>	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBONATE	PURITIES//Iron <241>							<i>Supplement to USP36–NF31</i>	<i>Sample solution:</i> Change <i>Sample solution:</i> Dissolve 1.0 g in 20 mL of water and 3 mL of hydrochloric acid. to: <i>Test preparation:</i> Dissolve 0.5 g in 20 mL of water and 3 mL of hydrochloric acid.
DELIVERABLE VOLUME	ACCEPTANCE CRITERIA/For Multiple-Unit Containers	<i>First Supplement to USP35–NF30</i>	5154	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<i>Figure 1</i> , right branch, left box: Change Volume of 1 more containers is less than 95% LV to: Volume of 1 or more containers is less than 95% LV
DIVALPROEX	PERFORMANC	<i>First</i>	5460	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First</i>	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM EXTENDED-RELEASE TABLETS	E TESTS/ <i>Dissolution</i> <711>/Test 3	<i>Supplement to USP35–NF30</i>						<i>Supplement to USP36–NF31</i>	Analysis: Change Samples: Acid stage standard solution, Buffer stage standard solution, Acid stage sample solutions, and Buffer stage sample solutions to: Samples: Acid stage standard solution, Buffer stage standard solution, and Sample solutions
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ <i>Dissolution</i> <711>	<i>First Supplement to USP35–NF30</i>	5473	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 4 of Medium: Change and adjust with 2 N hydrochloric acid or 2 N sodium, if necessary, to a pH to: and adjust with

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESOMEPRAZOLE IM LE PUR MAGNESIUM DITIES/ <i>Organic</i> ELAYED- <i>Impurities</i> RELEASE CAPSULES	<i>First Supplement to USP35–NF30</i>	5473	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	2 N hydrochloric acid or 2 N sodium hydroxide, if necessary, to a pH Line 1 of <i>Sample solution:</i> Change Transfer a portion of the powdered pellets, from the Capsule content, equivalent to 80–90 mg of esomeprazole, to a 200-mL volumetric flask, add 20 mL of methanol, and shake for 30 s. to: Transfer a portion of the powdered pellets (about 80–90 mg), from the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OMEGA-3-ACID ETHYL ESTERS CAPSULES	SPECIFIC TESTS/ <i>Microbial Enumeration Tests <61> and Tests for Specified Microorganisms <62></i>	<i>First Supplement to USP35–NF30</i>	5524	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>		Capsule content, to a 200-mL volumetric flask, add 20 mL of methanol, and shake for 30 s. Line 2: Change 10 ³ to: 10 ³ cfu/mL AND Line 3: Change 10 ² to: 10 ² cfu/mL AND Line 6: Change <i>Salmonella</i> in 10 g. to: <i>Salmonella</i> species in 10 g. Footnote h of Table 3: Change (3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13
TACROLIMUS IMPURITIES/ Procedure 2		<i>First Supplement to USP35–NF30</i>	5538	28-Sep-2012	1-Oct-2012	USP37–NF32	<i>First Supplement to USP36–NF31</i>		

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3- <i>{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}</i> -14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3 <i>H</i> -pyridine-2,1-c[[1,4]oxaazacyclotricosine-1,7,20,21(4 <i>H</i> ,23 <i>H</i>)-tetrone. to: (3 <i>S</i> ,4 <i>R</i> ,5 <i>S</i> ,8 <i>R</i> ,9 <i>E</i> ,12 <i>S</i> ,14 <i>S</i> ,15 <i>R</i> ,16 <i>S</i> ,18 <i>R</i> ,19 <i>R</i> ,26 <i>aS</i>)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TACROLIMUS CAPSULES	IM PURITIES/ Procedure 2	<i>First Supplement to USP35–NF30</i>	5541	28-Sep-2012		1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	3- $\{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl\}$ -14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3H-pyridido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone. Footnote j of Table 5: Change (3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3- $\{(E)-2-[(1R,3R,4$

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							<i>R</i>)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3<i>H</i> -pyridine-2,1-cyclo[1,4]oxaazacyclotricosine-1,7,20,21(4<i>H</i>,23<i>H</i>)-tetrone. to: (3<i>S</i>,4<i>R</i>,5<i>S</i>,8<i>R</i>,9<i>E</i>,12<i>S</i>,14<i>S</i>,15<i>R</i>,16<i>S</i>,18<i>R</i>,19<i>R</i>,26<i>aS</i>)-5,6,8, 11,12,13,14,15,16,17,18,19,24,25,26,26<i>a</i>-hexadecahydro-5,19-dihydroxy-3-[(<i>E</i>)-2-[(1<i>R</i>,3<i>R</i>,4<i>R</i>)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ELEMENTAL I DRUG MPURITIES—LISUBSTANCE MITS AND EXCIPIENTS	<i>Second Supplement to USP35–NF30</i>	5633	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3<i>H</i>-pyridine-2,1-cyclo[1,4]oxaazacyclotricosine-1,7,20,21(4<i>H</i>,23<i>H</i>)-tetrone. Rows 11 and 15 of <i>Column 2</i> of <i>Table 2</i>: Change 100 to: 10 AND Rows 11 and 15 of <i>Column 3</i> of <i>Table 2</i>: Change 10 to: 1.0 AND Row 11 of <i>Column 4</i> of <i>Table 2</i>:

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Change 1.5 to: 0.15 AND Row 15 of Column 4 of Table 2: Change 30 to: 3.0
ELEMENTAL I ANALYTICAL MPURITIES—LITESTING MITS	<i>Second Supplement to USP35–NF30</i>	5633	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Line 6: Change Pd to: Pb
ELEMENTAL I DRUG MPURITIES—LISUBSTANCE MITS AND EXCIPIENTS	<i>Second Supplement to USP35–NF30</i>	5633	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Row 13 of Column 4 of Table 2: Change 25 to: 1.0
ELEMENTAL I DRUG MPURITIES—LIP MITS RO DUCTS/ <i>Large Volume Parenterals</i>	<i>Second Supplement to USP35–NF30</i>	5633	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	Row 13 of Column 4 of Table 1: Change 250 to: 10
ELEMENTAL I INTRODUCTIO	<i>Second</i>	5634	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First</i>	Line 2 of <i>Target</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MPURITIES—P N/Definition ROCEDURES	<i>Supplement to USP35–NF30</i>					<i>Supplement to USP36–NF31</i>	<i>Elements: Change Pd to: Pb</i>
AZITHROMYCI IM N FOR INJECTION	<i>Second Supplement to of Aminoazithro mycin, Formamido Analog, Methylf ormamido Analog, and 3?-De(dimethylami no)-3?-oxoazithr omycin</i>	5910	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<i>Row 11 of Table 2: Change 3?-Demethyl-3?-N -[(4-methylphen yl)sulfonyl]azithr omycin to: 3?-N -D eme thyl-3?-N -[(4-methylphen yl)sulfonyl]azithr omycin</i>
AZITHROMYCI IM N FOR INJECTION	<i>Second Supplement to of Azithromycin N-Oxide, Desos aminylazithromy cin, and N-Dem ethylazithromy ci n</i>	5910	28-Sep-2012	1-Oct-2012	<i>USP37–NF32</i>	<i>First Supplement to USP36–NF31</i>	<i>Line 5 of Analysis: Change Result = $(r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$ to: Result = $(r_U/r_S) \times (C$</i>

Monograph Title Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							$\frac{s}{C_U}) \times P \times 100$

Pagination

- [First page](#) [« First](#)
- [Previous page](#) [« Previous](#)
- ...
- [Page 32](#)
- [Page 33](#)
- [Page 34](#)
- [Page 35](#)
- [Page 36](#)
- [Page 37](#)
- [Page 38](#)
- [Page 39](#)
- [Page 40](#)